Gene therapy hope for sickle cell: tiny trial tests One-Time fix

NCT ID NCT07436767

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a gene therapy called KL003 in just 3 people with severe sickle cell disease. The therapy uses the patient's own stem cells, modified to produce healthy hemoglobin, to reduce painful crises and the need for transfusions. The main goals are to see if the treatment is safe and if the new cells successfully engraft in the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KL003 cell injection (gene therapy using a patient's own stem cells modified to produce healthy hemoglobin)
What this could lead to: If it works, this could point toward a one-time treatment that reduces or eliminates painful crises and the need for blood transfusions in severe sickle cell disease.
What could go wrong: This is a very early, tiny trial with only 3 participants. It may fail to show benefit, and gene therapy carries risks like infection, immune reactions, or long-term side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.